Exosomes are the phospholipid-membrane-bound subpopulation of extracellular vesicles
derived from the plasma membrane. The main activity of exosomes is cellular …

The recent US Food and Drug Administration (FDA) approval of the dabrafenib/trametinib
combination as a tissue-agnostic treatment for solid tumors with BRAF V600E mutation is the …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Abstract Treatment with therapy targeting BRAF and MEK (BRAF/MEK) has revolutionized
care in melanoma and other cancers; however, therapeutic resistance is common and …

Background The outcome of patients with macroscopic stage III melanoma is poor.
Neoadjuvant treatment with ipilimumab plus nivolumab at the standard dosing schedule …

The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …

Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional
oncolytic immunotherapy approved for the treatment of unresectable melanoma. The …

The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous) provide
multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients …

Each year Clinical Cancer Advances: ASCO's Annual Report on Progress Against Cancer
highlights the most important clinical research advances of the past year, including the …

Neoadjuvant checkpoint inhibition, in which the therapy is administered before surgery, is a
promising new approach to managing bulky but resectable melanoma, and is also being …